Table 6.

Multivariate Cox proportional hazard analysis predicting shorter overall survival in patients with non‐small cell lung cancer treated with nivolumab

Variate	HR (95% CI)	P‐value
Age ≥75	0.70 (0.19–2.46)	0.579
Male gender	1.67 (0.54–5.21)	0.375
Heavy smoker	0.30 (0.10–0.86)	0.025
ECOG performance status ≥2	17.9 (5.17–62.0)	0.000
EGFR‐mutant	0.26 (0.05–1.28)	0.099
Squamous cell carcinoma	0.43 (0.15–1.30)	0.135
Interstitial septal thickening	3.44 (1.19–9.33)	0.099

CI, confidence interval; HR, hazard ratio.